Delivery Order SPE2DB22D3010-SPE2DB25FP3JT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $2,348.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 ml pen injections, with performance completion targeted for August 4, 2025. The contract, awarded August 1, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $44,409.63 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on July 30, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents a single transaction with a completion date of July 31, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a $18,956.21 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injectors (0.5 ml). The contract, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a $5,057.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections in 0.5 mL quantities. This non-set-aside competitive award is scheduled for completion by September 9, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $9,639.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. The contract, which is set to be completed by September 10, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive, non-set-aside award and is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3JTDelivery Order
The Defense Logistics Agency awarded a $11,204.83 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with an ultimate completion date of September 4, 2025. The contract, which is not set-aside and was competitively awarded, is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor providing critical medical supply support to defense and military healthcare systems. As a child delivery order under the SPE2DX IDC, this award reflects the company's role as a pharmaceutical prime vendor for the Defense Health Agency and related federal healthcare customers. The supply of Zepbound, a GLP-1 receptor agonist medication for weight management, aligns with the broader pharmaceutical supply mission of the IDC, which encompasses a comprehensive range of specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 9/3/25 |